242 related articles for article (PubMed ID: 30118897)
1. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
Leuk Res; 2018 Sep; 72():92-95. PubMed ID: 30118897
[No Abstract] [Full Text] [Related]
2. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
Haematologica; 2015 Sep; 100(9):1172-9. PubMed ID: 26022709
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
Zeidner JF; Lee DJ; Frattini M; Fine GD; Costas J; Kolibaba K; Anthony SP; Bearss D; Smith BD
Clin Cancer Res; 2021 Jan; 27(1):60-69. PubMed ID: 32998965
[TBL] [Abstract][Full Text] [Related]
4. Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?
van der Jagt RH
Leuk Res; 2010 Jul; 34(7):856-7. PubMed ID: 20378170
[No Abstract] [Full Text] [Related]
5. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
Röllig C; Kramer M; Gabrecht M; Hänel M; Herbst R; Kaiser U; Schmitz N; Kullmer J; Fetscher S; Link H; Mantovani-Löffler L; Krümpelmann U; Neuhaus T; Heits F; Einsele H; Ritter B; Bornhäuser M; Schetelig J; Thiede C; Mohr B; Schaich M; Platzbecker U; Schäfer-Eckart K; Krämer A; Berdel WE; Serve H; Ehninger G; Schuler US;
Ann Oncol; 2018 Apr; 29(4):973-978. PubMed ID: 29390048
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Karp JE; Garrett-Mayer E; Estey EH; Rudek MA; Smith BD; Greer JM; Drye DM; Mackey K; Dorcy KS; Gore SD; Levis MJ; McDevitt MA; Carraway HE; Pratz KW; Gladstone DE; Showel MM; Othus M; Doyle LA; Wright JJ; Pagel JM
Haematologica; 2012 Nov; 97(11):1736-42. PubMed ID: 22733022
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.
Wahlin A; Hörnsten P; Hedenus M; Malm C
Cancer Chemother Pharmacol; 1991; 28(6):480-3. PubMed ID: 1934252
[TBL] [Abstract][Full Text] [Related]
8. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
[TBL] [Abstract][Full Text] [Related]
9. Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia.
Jakl M; Horacek JM; Jebavy L; Pudil R
Leuk Res; 2009 Aug; 33(8):e109-10. PubMed ID: 19237194
[No Abstract] [Full Text] [Related]
10. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
[TBL] [Abstract][Full Text] [Related]
11. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Karp JE; Blackford A; Smith BD; Alino K; Seung AH; Bolaños-Meade J; Greer JM; Carraway HE; Gore SD; Jones RJ; Levis MJ; McDevitt MA; Doyle LA; Wright JJ
Leuk Res; 2010 Jul; 34(7):877-82. PubMed ID: 19962759
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Litzow MR; Wang XV; Carroll MP; Karp JE; Ketterling RP; Zhang Y; Kaufmann SH; Lazarus HM; Luger SM; Paietta EM; Pratz KW; Tun HW; Altman JK; Broun ER; Rybka WB; Rowe JM; Tallman MS
Am J Hematol; 2019 Jan; 94(1):111-117. PubMed ID: 30370956
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.
Ikezoe T; Ando K; Onozawa M; Yamane T; Hosono N; Morita Y; Kiguchi T; Iwasaki H; Miyamoto T; Matsubara K; Sugimoto S; Miyazaki Y; Kizaki M; Akashi K
Cancer Sci; 2022 Dec; 113(12):4258-4266. PubMed ID: 35689544
[TBL] [Abstract][Full Text] [Related]
14. [A systematic review of MA versus IA regimen for patients with acute myelogenous leukemia].
Wang WJ; Sun AN; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):869-70. PubMed ID: 22339965
[No Abstract] [Full Text] [Related]
15. A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.
Zeidner JF; Lin TL; Vigil CE; Fine G; Yair Levy M; Nazha A; Esteve J; Lee DJ; Yee K; Dalovisio A; Wang ES; Bergua Burgues JM; Schriber J; Litzow MR; Frankfurt O; Castillo TBD; Bhatt VR; Bhatnagar B; Mehta P; Dillon R; Vicente MV; Anthony S; Bearss D; Montesinos P; Douglas Smith B
Blood Cancer J; 2021 Oct; 11(10):175. PubMed ID: 34718324
[No Abstract] [Full Text] [Related]
16. Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemia.
Nachbaur K; Dietze O; Herold M; Thaler J; Braunsteiner H; Vogel W
Eur J Haematol; 1992 Oct; 49(4):221-3. PubMed ID: 1464366
[No Abstract] [Full Text] [Related]
17. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen.
Bow EJ; Loewen R; Cheang MS; Schacter B
Clin Infect Dis; 1995 Aug; 21(2):361-9. PubMed ID: 8562745
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
19. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
20. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Kim M; Williams S
Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
